2-(4-methylphenoxy)-5-trifluoromethylpyridine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(4-methylphenoxy)-5-trifluoromethylpyridine
• 英文别名: 2-(4-Methylphenoxy)-5-(trifluoromethyl)pyridine
• 化学式: C₁₃H₁₀F₃NO
• 分子量: 253.224
• InChiKey: OCXLCEFMMCMNCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• [EN] GLYCINE B ANTAGONISTS<br/>[FR] ANTAGONISTES DE LA GLYCINE B
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2010037533A1

  公开（公告）日：2010-04-08

  The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.

  该发明涉及喹啉衍生物及其药用盐。该发明还涉及一种制备这种化合物的方法。该发明的化合物是甘氨酸B拮抗剂，因此对于控制和预防各种疾病，包括神经系统疾病，非常有用。
• Functionalized Photoreactive Compounds
  申请人：Cherkaoui Mohammed Zoubair

  公开号：US20080274304A1

  公开（公告）日：2008-11-06

  The present invention concerns functionalized photoreactive compounds of formula (I), that are particularly useful in materials for the alignment of liquid crystals. Due to the adjunction of an electron withdrawing group to specific molecular systems bearing an unsaturation directly attached to two unsaturated ring systems, exceptionally high photosensitivities, excellent alignment properties as well as good mechanical robustness could be achieved in materials comprising said functionalized photoreactive compounds of the invention.

  本发明涉及式(I)的官能化光反应化合物，特别适用于液晶对准材料。由于在特定分子系统中的不饱和键直接连接到两个不饱和环系统上附加了一个电子受体基团，因此在包含本发明的这些官能化光反应化合物的材料中可以实现异常高的光敏性、优异的对准性能以及良好的机械稳健性。
• [EN] PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS<br/>[FR] PYRIMIDINE DIOL AMIDES COMME BLOQUEURS DES CANAUX SODIQUES
  申请人：PURDUE PHARMA LP

  公开号：WO2013072758A1

  公开（公告）日：2013-05-23

  The present disclosure provides pyrimidine diol amides of Formula (I), and the pharmaceutically acceptable solvates and prodrugs thereof, wherein A1, X, A2, W1, W2, W3, R1, R2, and R4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.

  本公开提供了式（I）的嘧啶二醇酰胺，以及其在药学上可接受的溶剂结晶和前药，其中A1、X、A2、W1、W2、W3、R1、R2和R4的定义如规范中所述。本公开还涉及使用式（I）的化合物来治疗对钠通道阻滞有反应的疾病。本公开的化合物特别适用于治疗疼痛。
• GLYCINE B ANTAGONIST
  申请人：Henrich Markus

  公开号：US20110190342A1

  公开（公告）日：2011-08-04

  The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.

  本发明涉及喹啉衍生物及其药学上可接受的盐。本发明还涉及制备这种化合物的过程。本发明的化合物是甘氨酸B拮抗剂，因此对控制和预防各种疾病，包括神经系统疾病，非常有用。
• SUBSTITUTED OXADIAZOLE COMPOUNDS
  申请人：Das Jagabandhu

  公开号：US20130190361A1

  公开（公告）日：2013-07-25

  Disclosed are compounds of Formula (I): or stereoisomers, N-oxides, salts, or prodrugs thereof; wherein: Ring A is phenyl or 5- to 6-membered heteroaryl; (i) R1 and R2 are independently C1-C4 alkyl; or (ii) R1 and R2 together with the carbon atom to which they are attached, form a cyclic group; Q is phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents; and R3, L1, L2, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及以下式(I)的化合物或其立体异构体、N-氧化物、盐或前药： 其中：环A是苯基或5-至6-成员杂环基； (i) R1和R2独立地是C1-C4烷基；或 (ii)R1和R2与它们连接的碳原子一起形成一个环状基团； Q是苯基或5-至6-成员杂环基，其被0-3个取代基取代；R3、L1、L2和n的定义详见说明书。 本发明还涉及将这些化合物用作选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在多种治疗领域中用于治疗、预防或减缓疾病或障碍的进展，如自身免疫性疾病和血管疾病。